Bradmer Pharmaceuticals Inc. to Present at Rodman & Renshaw Healthcare Conference
TORONTO, Nov. 3 /CNW/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical
company dedicated to the development and commercialization of cancer
therapies, announced today that Dr. Alan M. Ezrin, President and Chief
Executive Officer of the Company, will present a corporate update at Rodman &
Renshaw 10th Annual Healthcare Conference, which is being held in New York
City from November 10th - 12th at the New York Palace Hotel. Dr. Ezrin will
provide an update on the Company's ongoing GLASS-ART(TM) Trial, a Phase III
study evaluating Neuradiab(TM) as an adjunct therapy to the current standard
of care for newly diagnosed glioblastoma multiforme (GBM). The presentation
will take place on Wednesday, November 12th at 10:45am ET in the Kennedy I
Room and Dr. Ezrin will be available for questions following his presentation.